{"name":"Matinas BioPharma Nanotechnologies, Inc.","slug":"matinas-biopharma-nanotechnologies-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"MAT2203","genericName":"MAT2203","slug":"mat2203","indication":"Invasive fungal infections (including aspergillosis and candidiasis)","status":"phase_3"}]}],"pipeline":[{"name":"MAT2203","genericName":"MAT2203","slug":"mat2203","phase":"phase_3","mechanism":"MAT2203 is a lipid nanoparticle formulation of amphotericin B designed to improve drug delivery and reduce toxicity in fungal infections.","indications":["Invasive fungal infections (including aspergillosis and candidiasis)","Cryptococcal meningitis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOZGNicEtaZlJxeEtrZG05eUpTZXI2QmprS0htaWZWME9FcmhvZnR0VEJsSDNwa0VmeGhONjlOZ2hoaGxlcHBPaWNSZDBIbkREYzZibGFReHlPOTA2Nmw0M3NuUGd5aFVVUndwemhveWxoZTNUMHduY25aYXIwSTVjUWZMTVlNNFo1WVAxZzRsMTN6RjhqeHF6c0VRbkt5TFFZejJoNGRPTjhfSjkwX3RfNzlyd05uVEFE?oc=5","date":"2026-04-03","type":"pipeline","source":"Stock Titan","summary":"Matinas BioPharma has until May 2 to answer NYSE notice - Stock Titan","headline":"Matinas BioPharma has until May 2 to answer NYSE notice","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOY0dzVkprdlhEQnplRVFxTVJfZk9fTl9oOVcybjd3NWJXcWVJM1Frc3JvSGhLOTFyMUtOaHJZV0lNSTlmYmdDazNlOFJxcWppaVZCOHQ0MmF2MDdvekFFdkNNTEYxM3M0NzdCVW10dWEtSkRiYUlFZHBjVHRJOEgwNWZLNHFxalF2VnNia241b01odHYwaGEySnQ0aUlwdlJfdmhnZWRCRERzY3pMM3R3cGkzb1JraFUxT3RqSA?oc=5","date":"2026-04-03","type":"pipeline","source":"Stock Titan","summary":"Matinas BioPharma (NYSE American: MTNB) faces NYSE non-compliance and cure deadline - Stock Titan","headline":"Matinas BioPharma (NYSE American: MTNB) faces NYSE non-compliance and cure deadline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOOER6RVdLRUdDVTRlNUVHeV9uc0NudFFqWDhNRnBpUDcwMmF4UWo0R0xRMXJtUFZtQmtQVVBrYlFtdU1lM0E2VmFnUmNaVkUzcEpWaGFFbTg2MHg5ZW5iX29ndEg3RGF0bkQ4b25QdGFYNjVVMi1STjA2c2pvVkh2QUtWVU5MV0htOGhic0NDcm1PaVBwclBiME4teWpSYWVLVTlPMG04eFhoUnA1UkNLcVNmdmFGZ25RZktYS2tSNA?oc=5","date":"2024-10-31","type":"deal","source":"Pharmaceutical Technology","summary":"Matinas BioPharma mulls wind-down as antifungal therapy deal falls through - Pharmaceutical Technology","headline":"Matinas BioPharma mulls wind-down as antifungal therapy deal falls through","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}